Home > Focus Areas > COPD Connect > Post
  • Saved

made a Post

3yr
The importance of treating COPD early

Early COPD can refer to the destruction/loss of the terminal/transitional bronchioles that arises before a deterioration in lung function is demonstrated. It can manifest in the absence of emphysematous destruction, with surviving airways exhibiting narrowed lumens/thickened walls. Defining “early COPD” can be challenging, with the 2023 Global Initiative for Obstructive Lung Disease (GOLD) guidelines preferring a “biologic” to “clinical” definition.



According to the 2023 Global GOLD guidelines, all COPD patients can be started on a long-acting muscarinic antagonist (LAMA), with treatment increases as needed. Treatments should be tailored based on patient needs. Furthermore, the report recommends LAMA plus long-acting beta-agonist (LABA) as initial treatment option in Group B and Group E COPD patients, with single inhalers being a more convenient/effective option than multiple inhalers.



Data suggest that the LAMA, tiotropium bromide, enhances lung function, slows annual declines in FEV, and decreases the need for rescue inhalers. Moreover, findings from short- and long-term randomized, controlled clinical trials involving tiotropium use in COPD patients have suggested that it is safe and improves health-related quality of life and exercise endurance when compared with placebo or active comparators. It also reduces dyspnea and lung hyperinflation.



Tiotropium bromide inhalation spray is the only LAMA that delivers a soft mist designed to be gentler on damaged lungs because use of the soft mist inhaler (SMI) requires minimal inspiratory effort vs. other inhaler types.



What is your protocol for initiating early treatment in COPD patients? What have your experiences been with tiotropium bromide soft mist inhalation spray?

 

  • 3yr
    Typically driven by patient factors. I don't see very many mild patients but might consider single bronchodilator therapy. LAMA usually, maybe ICS/LABA if possible asthma component. Otherwise typically use LABA/LAMA for more symptomatic patients nowdays. Add ICS if asthma component or show signs of exacerbation potential. Nebulizers if questionable proper inahler use.
  • 3yr
    triple therapies work best
  • 3yr
    Recent new guideline enforces and confirms what we have known over the last 10-15 years about LAMA which is better tolerated than LABA/ICS for most patients. Meanwhile it provides some clinical data and suggestions on initiation of LABA/LAMA vs LABA/ICS therapy.
  • 3yr
    Upon review of the other comments, my practice is very similar. Very few patients in Pulmonary Clinic with mild COPD (selection bias), so not too many on LAMA or LABA in isolation (usually preferring a LAMA). Most on LAMA/LABA to start, with trying to adhere to the usual indications to escalate to triple therapy. To quote Dr. Kashyap above, "I reserve my nebulizer treatment for patients who are unable to use inhalers properly either due to their poor respiratory effort or neuromuscular weakness", but will also use nebulized therapies for cost/coverage via Medicare part B when costs are high for inhalers through part D.
  • 3yr
    My approach has been to initiate LAMA with PRN SABA. For second line therapy I add LABA/ICS or change the treatment to triple combination therapy (LAMA/LABA/ICS).
    I reserve my nebulizer treatment for patients who are unable to use inhalers properly either due to their poor respiratory effort or neuromuscular weakness
  • 3yr
    I think current data suggests laba-lama as first maintenance drug for those with anything more than mild COPD, along with short acting beta agonists. limited in part by insurance plans coverage for various drugs and step edits we are forced to go thru
  • 3yr
    I try to adhere to the GOLD guidelines and usually initiate a LAMA. I find most have been using SABA, so I tend to already introduce a LAMA/LABA combination production to reduce the use of the SABA. Many times product choices are limited by formularies and paperwork in the form of prior authorizations. When I can get the Tiotropium SMI approved, most patient tend to prefer it. I am told they feel they are 'getting the medicine' as opposed to other inhalers. It is described as similar to using a nebulizer and requires minimal effort with inhalation.

Show More Comments